Oral Rybelsus Now a First-Line Option in Treatment of Type 2 Diabetes
In January, the U.S. Food and Drug Administration (FDA) cleared Novo Nordisk’s once-daily Rybelsus (semaglutide) oral tablets as a first-line treatment to improve…Original Article
Monthly News Roundup – January 2023
Oral Rybelsus Now a First-Line Option in Treatment of Type 2 Diabetes
In January, the U.S. Food and Drug Administration (FDA) cleared Novo Nordisk’s once-daily Rybelsus (semaglutide) oral tablets as a first-line treatment to improve…
